REG - Tissue Regenix Group - New sports medicine product launch

Tissue RegenixAnnouncement

05/09/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230905:nRSE3331La&default-theme=true

RNS Number : 3331L  Tissue Regenix Group PLC  05 September 2023

Tissue Regenix Group plc

('Tissue Regenix', the 'Group' or the 'Company')

 

New sports medicine product launch

 

Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company,
announces the launch of its new BioRinse® product line for all sports
medicine allografts that Tissue Regenix distributes in the US and
internationally.

 

The Company's BioRinse sterilisation technology platform uses proprietary
processes to produce sterile bone and soft tissue products. The new process
for sports medicine allografts causes less damage to the tissue in order to
produce an enhanced sterile soft tissue product. The primary market for these
grafts is sports medicine, mainly consisting of tendon and ligament
reconstruction procedures in the knee, ankle, elbow, and other joints.

 

The Company has previously discussed plans to innovate the processing
protocols for its soft tissue products in order to enhance performance,
efficiency, and safety in the products that Tissue Regenix already produces
for the sports medicine market. These changes will allow Tissue Regenix to
capture a larger segment of the estimated USD300 million market for allograft
soft tissue tendons for ligament reconstruction procedures of the knee.

 

Daniel Lee, Chief Executive Officer of Tissue Regenix, commented: "As part of
our ongoing initiatives to provide high-quality products to our customers, we
continually monitor market dynamics and customer needs. With the launch of our
new product, we are offering an enhanced tissue allograft option. The initial
reaction of our commercial partners has been positive and will aid our
commercial efforts in both the domestic and rest of the world markets."

 

For more information:

 

 Tissue Regenix Group plc                                           www.tissueregenix.com (http://www.tissueregenix.com)
 David Cocke, Chief Financial Officer                               via Walbrook PR

 finnCap Ltd (Nominated Adviser and Broker)
 Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
 Nigel Birks/Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)  Tel: +44 (0)20 7933 8780
 Alice Woodings/Lianne Applegarth   TissueRegenix@walbrookpr.com

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries, and
wound care.

 

In August 2017, Tissue Regenix acquired CellRight Technologies®. This
biotech company specialises in regenerative medicine and is dedicated to
developing high-quality, innovative tissue scaffolds to enhance healing
opportunities in defects created by trauma and disease. CellRight's human
tissue products may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLQZLFBXKLXBBB